Atropine, chlorpheniramine, phenylpropanolamine (Contac)
Atropine, chlorpheniramine, phenylpropanolamine
Smith Kline French (Pty) Ltd *
Every registration of this product has been cancelled.
Registration
- Applicant
- Smith Kline French (Pty) Ltd *
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Contac 600 CAPSULE ATROPINE SULPHATE A 0,0375 MG CHLORPHENIRAMINE MALEATE A 3,2 MG HYOSCINE HYDROBROMIDE A 0,0219 HYOSCYAMINE SULPHATE A 0,1906 PHENYLPROPANOLAMINE HYDROCHLORIDE A 40 MG | 600 | C0630 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S6: Phenylpropanolamine
- except products registered in terms of the Act, not intended for export and oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S2)
Consolidated Schedules 06 July 2026, lines 10387 to 10394
S4: Atropine
- when intended for use in injections. (S2)
- except when intended for use in ophthalmic preparations. (S3)
Consolidated Schedules 06 July 2026, lines 5387 to 5391
S3: Atropine
- when intended for use in ophthalmic preparations; (S2)
- except when intended for use in injections. (S4)
Consolidated Schedules 06 July 2026, lines 3150 to 3154
S2: Atropine
- when intended for use in ophthalmic preparations; (S3)
- when intended for use in injections. (S4)
Consolidated Schedules 06 July 2026, lines 1631 to 1635
S2: Chlorpheniramine
Consolidated Schedules 06 July 2026, line 1732
S2: Phenylpropanolamine
- contained in products registered in terms of the Act, and not intended for export, unless listed separately in the Schedules,
- oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S6)
Consolidated Schedules 06 July 2026, lines 2516 to 2523
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.